Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial.

ABSTRACT:

Background

Few treatment options are available for patients with epidermal growth factor receptor (EGFR) mutation-positive metastatic non-squamous non-small cell lung cancer (NSCLC) who failed treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs). We aimed to assess the efficacy and safety of atezolizumab plus bevacizumab in these patients.

Methods

We conducted a single-arm, Simon's minimax two-stage adapted phase II study. Patients received atezolizumab 1200 mg plus bevacizumab 15 mg/kg once every 3 weeks. The primary endpoint was the objective response rate (ORR). Secondary endpoints included duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and safety.

Results

Between 14 August 2020 and 18 January 2021,

SUBMITTER: Fang W 

PROVIDER: S-EPMC12701562 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature